Status:
UNKNOWN
Metabolic Consequences of Cross-sex Hormonal Treatment
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Gender Dysphoria
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-a...
Eligibility Criteria
Inclusion
- Inclusion Criteria (retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits)
- age \>= 16 years (Tanner stage IV) and \<= 50 years at the initiation of gender-affirming hormone therapy;
- BMI \< 28 kg/m2 at the initiation of cross-sex hormonal treatment.
- Exclusion Criteria:
- hormonal contraception
- previous gender-affirming hormonal treatment
- previous gender-affirming surgery
- recognized syndrome or chromosomal defect, known metabolic or inflammatory disease, skeletal dysplasia, or chronic corticosteroid treatment.
Exclusion
Key Trial Info
Start Date :
July 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT04508231
Start Date
July 24 2020
End Date
December 1 2021
Last Update
August 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Nancy
Nancy, France, 54000